Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial | Zendy

Andrew Zolopa | Zendy; Daniel S Berger | Zendy; Harry Lampiris | Zendy; Lijie Zhong | Zendy; Steven L. Chuck | Zendy; Jeffrey Enejosa | Zendy; Brian P. Kearney | Zendy; Andrew Cheng | Zendy

Open Access

Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial

Author(s) -

Andrew Zolopa,

Daniel S Berger,

Harry Lampiris,

Lijie Zhong,

Steven L. Chuck,

Jeffrey Enejosa,

Brian P. Kearney,

Andrew Cheng

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/650698

Subject(s) - elvitegravir , ritonavir , medicine , integrase inhibitor , darunavir , virology , pharmacology , randomized controlled trial , cobicistat , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy

This phase 2, randomized, active-controlled, 48-week study assessed the noninferiority of the human immunodeficiency virus (HIV) integrase inhibitor elvitegravir to comparator ritonavir-boosted protease inhibitor (CPI/r) in treatment-experienced subjects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research